[1]任勇军,闵旭立,徐 浩,等.洛铂联合表柔比星化疗栓塞治疗原发性肝细胞癌的疗效[J].医学信息,2019,32(24):43-46.[doi:10.3969/j.issn.1006-1959.2019.24.014]
　REN Yong-jun,MIN Xu-li,XU Hao,et al.Efficacy of Loplatin Combined with Epirubicin Chemotherapy and Embolization for Primary Hepatocellular Carcinoma[J].Medical Information,2019,32(24):43-46.[doi:10.3969/j.issn.1006-1959.2019.24.014]
点击复制

洛铂联合表柔比星化疗栓塞治疗原发性肝细胞癌的疗效()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
32卷
期数:
2019年24期
页码:
43-46
栏目:
论著
出版日期:
2019-12-15

文章信息/Info

Title:
Efficacy of Loplatin Combined with Epirubicin Chemotherapy and Embolization for Primary Hepatocellular Carcinoma
文章编号:
1006-1959（2019）24-0043-04
作者:
任勇军; 闵旭立; 徐 浩; 刘 帆; 陈智粮; 贺 颖
（川北医学院附属医院介入放射科/四川省医学影像重点实验室，四川 南充 637000）
Author(s):
REN Yong-jun; MIN Xu-li; XU Hao; LIU Fan; CHEN Zhi-liang; HE Ying
(Department of Interventional Radiology,Affiliated Hospital of North Sichuan Medical College/Sichuan Key Laboratory of Medical Imaging,Nanchong 637000,Sichuan,China)
关键词:
肝癌; 经皮肝动脉化疗栓塞术; 洛铂; 表柔比星; 顺铂
Keywords:
Liver cancer; Percutaneous transcatheter arterial chemoembolization;  Loplatin; Epirubicin; Cisplatin
分类号:
R714.246
DOI:
10.3969/j.issn.1006-1959.2019.24.014
文献标志码:
A
摘要:
目的 观察洛铂联合表柔比星化疗栓塞治疗原发性肝细胞肝癌的近远期疗效及安全性。方法 收集 2014年1月~2016年12月我院收治的原发性肝细胞肝癌患者133例，所有患者接受灌注化疗和化疗栓塞治疗，根据治疗方案分为实验组（71例）和对照组（62例），实验组采用洛铂联合表柔比星治疗；对照组接受顺铂联合表柔比星治疗；比较两组近期疗效、远期疗效、肝功能（ALP、ALT、AST、TBIL）及毒副反应。结果 实验组近期总有效率为87.32%，高于对照组的69.35%，差异有统计学意义（P＜0.05）；治疗6、12个月后，两组生存率比较，差异无统计学意义（P＞0.05）；治疗18、24 个月后，观察组生存率均高于对照组，差异有统计学意义（P＜0.05）；治疗后，两组ALP、ALT比较，差异无统计学意义（P＞0.05），但实验组AST低于对照组、TBIL高于对照组，差异均有统计学意义（P＜0.05）；实验组胃肠道反应、骨髓抑制及肾脏毒性发生率均低于对照组，差异有统计学意义（P＜0.05）。结论 洛铂联合表柔比星化疗栓塞治疗原发性肝细胞肝癌近期疗效及患者远期生存期率高于顺铂联合表柔比星，其肝功能损害和毒副反应轻，患者耐受性较好。
Abstract:
Objective To observe the short-term and long-term efficacy and safety of loplatin combined with epirubicin chemotherapy and embolization in the treatment of primary hepatocellular carcinoma. Methods A total of 133 patients with primary hepatocellular carcinoma treated in our hospital from January 2014 to December 2016 were collected. All patients received perfusion chemotherapy and chemoembolization. They were divided into experimental group (71 cases) and control group ( 62 cases), the experimental group was treated with loplatin combined with epirubicin; the control group was treated with cisplatin combined with epirubicin; the short-term efficacy, long-term efficacy, liver function (ALP, ALT, AST, TBIL) and Toxic side effects. Results The recent total effective rate of the experimental group was 87.32%, which was higher than the 69.35% of the control group,the difference was statistically significant (P<0.05). After 6 and 12 months of treatment, the survival rates of the two groups were not statistically significant (P>0.05); After 18 and 24 months of treatment, the survival rate of the observation group was higher than that of the control group,the difference was statistically significant (P<0.05). After treatment, there was no statistically significant difference in ALP and ALT between the two groups (P＞0.05), but the AST in the experimental group was lower than that in the control group, and the TBIL was higher than the control group,the differences were statistically significant (P＜0.05). The incidence of gastrointestinal reactions, bone marrow suppression, and renal toxicity in the experimental group were lower than those in the control group,the differences were statistically significant (P<0.05). Conclusion The short-term efficacy and long-term survival rate of patients with primary hepatocellular carcinoma treated with loplatin combined with epirubicin chemoembolization are higher than those of cisplatin combined with epirubicin, which has less liver damage and toxic side effects and is well tolerated.

参考文献/References:

[1]Jian Z,Hui-Chuan S,Zheng W,et al.Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition)[J].Liver Cancer,2018,7(3):235-260.[2]Cheng S,Chen M,Cai J,et al.Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus: 2016 edition[J].Oncotarget,2017,8(5):8867-8876.[3]Llovet JM,Real MI,Montana X,et al.Arterial embolisation or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma:a randomised controlled trial[J].Lancet,2002,359(9319):1734-1739.[4]石明,陈继安,林小军,等.肝动脉栓塞化疗不同化疗方案治疗不可切除肝癌的前瞻性随机对照研究[J].中国肿瘤临床,2009,36(1):9-13.[5]Branch of Interventon,Chinese Medical Doctor Association.The expert consensus of LobapIatin for Injection in the treatment of TACE for primary Iiver cancer(2016 Edition)[J/CD].Chin J Inter Rad,2016,4(1):1-3.[6]钱军,秦叔逵,杨爱珍,等.不同铂类药物对人肝癌细胞株抑制作用的实验研究[J].临床肿瘤学杂志,2009,14(5):414-417.[7]李莹莹,詹丽芬,曾哲超,等.洛铂对肝癌HepG2细胞增殖和调亡的作用及机制[J].临床肝胆病杂志,2018,34(4):784-788.[8]中国医师协会介入医师分会.注射用洛铂在原发性肝癌TACE治疗中的专家共识（2016版）[J].中华介入放射学电子杂志,2016,4(1):1-3.[9]Sutherland A,Naessens K,Plugge E,et al.Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults[J].Cochrane Database Syst Rev,2018(9):CD012555.[10]Edeline J,Boucher E,Rolland Y,et al.Comparison of tumorresponse by response evaluation criteria in solid tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma[J].Cancer,2012(118):147-156.[11]Lo CM,Ngan H,Tso WK,et al.Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma[J].Hepatology,2002,35(5):1164-1171.[12]Wang Y,Zheng WL,Ma WL.Lobaplatin Inhibits the Proliferation of Hepatollular Carcinoma Through P53 Apoptosis Axis[J].Hepat Mon,2012,12(10):e6024.[13]郭雯莹,薛挥,隋东虎.洛铂联合碘化油栓塞治疗原发性肝癌的临床研究[J].陕西医学杂志,2015,44(2):230-232.[14]卜阳,于松宁.5-FU与洛铂对原发性肝癌晚期患者血清AFP及TIP30水平的影响[J].中国生化药物杂志,2016,11(36):68-72.[15]唐鑫,刘玉宇,敬方园,等.洛铂联合三氧化二砷TACE治疗老年原发性肝癌的临床疗效观察[J].介入放射学杂志,2017,26(12):1136-1139.[16]Wang Y,Ma L,Yuan Z,et al.Percutaneous thermal ablation combined with TACE versus TACE monotherapy in the treatment for liver cancer with hepatic vein tumor thrombus:A retrospective study[J].PLoS One,2018,13(7):e0201525.

相似文献/References:

[1]修朋程,李 腾,李雅林,等.泰山山慈菇对小鼠肝癌的治疗作用及相关免疫机制研究[J].医学信息,2018,31(09):8.[doi:10.3969/j.issn.1006-1959.2018.09.003]
　XIU Peng-cheng,LI Teng,LI Ya-lin,et al.Study on the Therapeutic Effect and Mechanism of Taishan Mountain Mushroom on Liver Cancer in Mice[J].Medical Information,2018,31(24):8.[doi:10.3969/j.issn.1006-1959.2018.09.003]
[2]崔康健,杜成友.肝动脉化疗栓塞联合射频消融治疗肝癌的研究进展[J].医学信息,2018,31(09):16.[doi:10.3969/j.issn.1006-1959.2018.09.005]
　CUI Kang-jian,DU Cheng-you.Research Progress of Transcatheter Arterial Chemoembolization Combined with Radiofrequency Ablation for Liver Cancer[J].Medical Information,2018,31(24):16.[doi:10.3969/j.issn.1006-1959.2018.09.005]
[3]田 明,常伟平.UbcH10在肝癌中的表达及其与预后的关系[J].医学信息,2019,32(12):77.[doi:10.3969/j.issn.1006-1959.2019.12.024]
　IAN Ming,CHANG Wei-ping.Expression of UbcH10 in Hepatocellular Carcinoma and Its Relationship with Prognosis[J].Medical Information,2019,32(24):77.[doi:10.3969/j.issn.1006-1959.2019.12.024]
[4]许 吉.基于知识图谱和专利地图的我国抗肝癌药物研发态势研究[J].医学信息,2018,31(21):19.[doi:10.3969/j.issn.1006-1959.2018.21.007]
　XU Ji.Research and Development Situation of Anti-liver Cancer Drugs in China Based on Knowledge Map and Patent Map[J].Medical Information,2018,31(24):19.[doi:10.3969/j.issn.1006-1959.2018.21.007]
[5]兰福全,李秀云,卢 斌.四种肿瘤标志物对肝癌诊断的临床意义[J].医学信息,2018,31(21):164.[doi:10.3969/j.issn.1006-1959.2018.21.048]
　LAN Fu-quan,LI Xiu-yun,LU Bin.The Clinical Significance of Four Tumor Markers in the Diagnosis of Liver Cancer[J].Medical Information,2018,31(24):164.[doi:10.3969/j.issn.1006-1959.2018.21.048]
[6]李 闯,叶劲松,刘 昕,等.ZBP-89与缺氧信号因子HIF-1α在肝癌细胞中的 相关性研究[J].医学信息,2019,32(15):74.[doi:10.3969/j.issn.1006-1959.2019.15.023]
　LI Chuang,YE Jin-song,LIU Xin,et al.Correlation between ZBP-89 and Hypoxia Signaling Factor HIF-1α in Hepatoma Cells[J].Medical Information,2019,32(24):74.[doi:10.3969/j.issn.1006-1959.2019.15.023]
[7]赵瑶瑶,高 川,胡佳杰.循环miRNA监测肝细癌的研究[J].医学信息,2019,32(08):48.[doi:10.3969/j.issn.1006-1959.2019.08.016]
　ZHAO Yao-yao,GAO Chuan,HU Jia-jie.Research on the Study of Circulating miRNA for Monitoring Hepatocellular Carcinoma[J].Medical Information,2019,32(24):48.[doi:10.3969/j.issn.1006-1959.2019.08.016]
[8]孙 逊.性化护理对肝癌患者CT引导下射频消融术后 负性情绪及生活质量的影响[J].医学信息,2019,32(17):187.[doi:10.3969/j.issn.1006-1959.2019.17.065]
　SUN Xun.Effect of Humanized Nursing on Negative Emotion and Quality of Life after CT-guided Radiofrequency Ablation in Patients with Liver Cancer[J].Medical Information,2019,32(24):187.[doi:10.3969/j.issn.1006-1959.2019.17.065]
[9]徐 蓓,魏霞丽,常艳琴.肝癌患者术后自我饮食管理体验的质性研究[J].医学信息,2019,32(20):180.[doi:10.3969/j.issn.1006-1959.2019.20.058]
　XU Bei,WEI Xia-li,CHANG Yan-qin.Qualitative Study of Postoperative Self-Catering Management Experience in Patients with Liver Cancer[J].Medical Information,2019,32(24):180.[doi:10.3969/j.issn.1006-1959.2019.20.058]
[10]刘申颖,施彦卿,梅鹏飞,等.超声引导下经皮无水乙醇注射联合射频消融治疗中晚期肝癌的效果[J].医学信息,2019,32(22):87.[doi:10.3969/j.issn.1006-1959.2019.22.026]
　LIU Shen-ying,SHI Yan-qing,MEI Peng-fei,et al.Ultrasound-guided Percutaneous Ethanol Injection Combined with Radiofrequency Ablation for Advanced Hepatocellular Carcinoma[J].Medical Information,2019,32(24):87.[doi:10.3969/j.issn.1006-1959.2019.22.026]

更新日期/Last Update: 2019-12-15